Branded

Regeneron’s Inmazeb is the first FDA-approved treatment for Ebola virus infection in adult and pediatric patients.

Sunovion’s Kynmobi is the first and only sublingual therapy for the on-demand treatment of off episodes in patients with Parkinson’s disease.

Bristol-Myers Squibb’s Opdivo, in combination with Yervoy, was approved by the FDA as a treatment for adults with malignant pleural mesothelioma that can't be removed by surgery.

Eton’s Alkindi Sprinkle is the first and only granular hydrocortisone formulation for adrenocortical insufficiency for children approved by the Food and Drug Administration.

GSK’s Nucala has received the Food and Drug Administration’s approval for patients with HES, a group of rare blood disorders.

Vertex's Kalydeco, which was first approved in 2012, has received the FDA nod for an expanded indication that will provide a Cystic Fibrosis treatment for children ages four months to less than six months old.

Teva Respiratory's AirDuo Digihaler and ArmonAir Digihaler contain built-in Bluetooth technology, enabling connection with a companion mobile app.

Trelegy Ellipta is now approved for the treatment of COPD and asthma.